0830 GMT - Novo Nordisk's sales guidance is materially ahead of expectations, Intron Health's Naresh Chouhan writes. The company expects sales to grow 16%-24% this year with EBIT growing 19%-27%. Fourth-quarter EBIT beat expectations by 9% as the gross margin beat by 140 basis points and the EBIT margin beat by 170 basis points. "Given recent concerns on growth, we expect the shares to be up strongly this morning given the sales guidance is materially higher than consensus was expecting and Wegovy was in-line," Chouhan says. Shares trade 4.3% higher at 617.90 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 03:30 ET (08:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。